OHSU Knight Cancer Institute

01/09/2026

During a segment on College GameDay before the Orange Bowl, both Coach Dan Lanning and Pat McAfee Show generously donated $100K each to the OHSU Knight Cancer Institute!

Appreciate you, Coach and Pat! Best of luck tonight in the Peach Bowl 🦆

Dan Lanning missed Pat McAfee's GameDay challenge but still committed $100K of his own money. Here's what happened.

01/06/2026

“The Community Partnership Program has helped us to make this program possible.

Last year we helped more than 300 cancer patients and caregivers through our cancer support program, and we look forward to helping even more.”

- Erik Szeto, founder of the Asian Health and Service Center:

The Community Partnership Program invests in programs across Oregon designed by local communities, for local communities.

12/31/2025

OHSU researchers analyzed more than 300 acute myeloid leukemia, or AML, patient samples and found that pairing venetoclax, a standard AML drug, with palbociclib, a cell-cycle inhibitor currently approved for breast cancer, produced significantly stronger and more durable anti-leukemia activity than venetoclax alone.

More than 20,000 Americans are diagnosed with AML each year, making it one of the most common types of leukemia — and one of the most aggressive. https://bit.ly/4sprXTt

Scientists identified a new drug combination that could overcome treatment resistance in acute myeloid leukemia.

12/30/2025

"Having a blood test that detects a signal for a cancer in somebody with no symptoms and then seeing it confirmed on imaging? It’s a game-changer. It’s completely revolutionary." - Nima Nabavizadeh, MD, Chief medical officer for the OHSU Knight Cancer Institute's Cancer Early Detection Advanced Research Center, or CEDAR.

Dr. Nabavizadeh is the principal investigator for the PATHFINDER 2 study, the largest interventional multi-cancer early detection, or MCED, trial in North America examining the safety and efficacy of Grail’s Galleri MCED blood test to screen for cancers.

OHSU radiation oncologist presents promising study findings, launches a third, Medicare-backed study.

12/23/2025

This season of giving, help us at OHSU do what we do best — provide exceptional health care for those in need in our community — by making a gift today.

Your generosity will make the new year bright and ignite hope for OHSU and Doernbecher Children’s Hospital patients, health care professionals, scientists, students, and communities: https://bit.ly/4pU5qMO

12/20/2025

OHSU patient, Matt Hazard battles colorectal cancer on his journey to race in the Boston Marathon 🏃‍♂️💪🔔

12/19/2025

“Patients with brain cancer are often left feeling frustrated trying to understand their tumor’s progression and what the right treatment is.

Now with a new path forward, we hope patients are provided some hope and comfort in this extremely difficult moment.”

- Dr. Ramon Barajas on new anemia drug used in brain cancer imaging ⤵️

OHSU lab started exploring new use of the drug 30 years ago; now, it may improve techniques to measure, monitor aggressive brain tumors.

12/12/2025

For Matt Hazard, there may not have been a better decision than listening to his cousin, who urged him to get a colonoscopy.

“Matt’s story is one of perseverance. He has a fantastic attitude, and we are so proud of him,” says Dr. Nima Nabavizadeh.

He received targeted, specialized care at OHSU for his colorectal cancer diagnosis, all while training for the Boston Marathon.

“I’m not going to stop running. I’m going to trust my body and try to put myself in the best position to fight this.”

After completing the marathon, Matt is on the road to recovery and has since turned his attention to advocacy for early cancer screenings.

Matt Hazard received personalized, multidisciplinary care at OHSU that allowed him to overcome cancer, inspire others to get colonoscopies.

12/12/2025

“We’re now identifying many survivors six years out, which is remarkable for a population that had very few options and very limited expectations for any meaningful survival.”

- Dr. Richard Maziarz on new data confirming the success of OHSU's CAR-T therapy.

Five-year data from clinical trial for adults with relapsed or refractory large B-cell lymphoma confirms lasting remissions in high-risk patients.

12/08/2025

“Health care in this country is facing obstacles like never before. The attack on biomedical research funding is unprecedented.”

Drs. Lisa Coussens, Shivaani Kummar, and Shannon McWeeney discuss the challenges and opportunities impacting our state’s cancer research ecosystem and what is needed to maintain and accelerate the pace of innovation with the Portland Business Journal:

Recently, The Kuni Foundation sponsored a conversation with the Portland Business Journal about the challenges and opportunities impacting our state’s cancer research ecosystem, and what is needed to maintain and accelerate the pace of innovation.

12/04/2025

Oregon is a place where nature, science, and technology thrive together. Our state is home to a vibrant community of world-class researchers and innovators across our public universities.

Link Oregon is Oregon’s state-of-the-art fiber optic network for government, research, and education, providing the speed and capacity necessary for advanced research initiatives among our universities and institutions. The ability to share data is helping researchers and students alike innovate across the state.

Dr. Shannon McWeeney, Chief Data Officer and Associate Director of Data Science, discusses the importance of data sharing and collaboration.

“To me, science is absolutely a team sport,” Dr. McWeeney said. “We cannot do this alone, given the vast complexities of the problems we’re trying to tackle to improve the outcomes of our patients."

12/02/2025

This , the OHSU community is uniting to make an impact, and we hope you’ll join us.

Begin your season of giving by benefiting life-saving programs, new treatments and cures, and education for tomorrow’s health leaders at OHSU.

Donate today: https://bit.ly/493XlNL